Letrozole tops aspirin for halting ovarian hyperstimulation

January 5, 2017

(HealthDay)—For high-risk women, letrozole is more effective than aspirin for decreasing the incidence of moderate and severe early-onset ovarian hyperstimulation syndrome, according to a study published in the January issue of the American Journal of Obstetrics & Gynecology.

Qingyun Mai, M.D., Ph.D., from the First Affiliated Hospital of Sun Yat-sen University in Guangzhou, China, and colleagues compared the efficacy of letrozole with aspirin in primary prevention of early ovarian hyperstimulation syndrome in a . Data were included for 238 participants undergoing cryopreservation of the whole embryos after oocyte retrieval with at least one high-risk factor for ovarian hyperstimulation syndrome. After triggering, experimental and control groups (119 participants in each) received five days of letrozole and aspirin.

The researchers found that women receiving aspirin versus letrozole had significantly higher incidence of ovarian hyperstimulation syndrome (90.2 versus 80.4 percent, respectively). The aspirin group also had significantly higher incidence of moderate and severe ovarian hyperstimulation syndrome (45.1 versus 25.0 percent). Compared with the aspirin group, the letrozole group had a significantly shortened duration of the luteal phase (8.1 ± 1.1 days versus 10.5 ± 1.9 days). The letrozole group had a significantly higher vascular endothelial growth factor level than the aspirin group (0.49 ± 0.26 versus 0.42 ± 0.22).

"Letrozole was more effective than aspirin in decreasing the incidence of moderate and severe early-onset ovarian hyperstimulation ," the authors write.

Explore further: Palbociclib efficacious in metastatic breast cancer

More information: Full Text (subscription or payment may be required)

Related Stories

Cilostazol doesn't prevent periprocedural MI in ACS

May 9, 2016

(HealthDay)—For patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), adjunctive loading dose of cilostazol is not associated with prevention of periprocedural myocardial infarction ...

Letrozole tied to ovarian function recovery in chemo

February 18, 2016

(HealthDay)—Some women aged 40 to 49 years with estrogen receptor-positive breast cancer who undergo chemotherapy-induced amenorrhea regain ovarian function with letrozole, according to a study published online Feb. 16 ...

Letrozole may help women with PCOS become pregnant

July 9, 2014

The drug letrozole results in higher birth rates in women with polycystic ovary syndrome (PCOS) than the current preferred infertility treatment drug, according to a nationwide study led by Penn State College of Medicine ...

Recommended for you

Technique for 'three-parent baby' revealed

April 3, 2017

Details of a pioneering IVF technique using mitochondrial replacement therapy (MRT) have been revealed, giving hope to those families with inheritable mitochondrial disorders that they may be able to have healthy children ...

Technology to screen embryos before implantation falls short

March 31, 2017

The healthy development of an embryo created through in vitro fertilization (IVF) depends on whether most, if not all, of the cells have the proper number of chromosomes. With pre-implantation genetic screening (PGS) technology, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.